ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition
Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 6, 2019, announcing the results of operations of Eli Lilly and Company (“Lilly”) for the fourth quarter and fiscal year ended December 31, 2018 (the “Reported Periods”), including, among other things, unaudited operating results for those periods.
Item 8.01. Other Events
The information contained in Exhibit 99.1 (other than the quote from David A. Ricks, the Company’s Chief Executive Officer, the Company’s non-GAAP financial results for the Reported Periods, the Company’s non-GAAP guidance for 2019 and the reconciliations related thereto) is hereby incorporated by reference.
Item 9.01. Financial Statements and Exhibits
Exhibit NumberDescription
99.1Press release dated February 6, 2019, together with related attachments.
LILLY ELI & CO Exhibit
EX-99.1 2 q418lillysalesandearningsp.htm EXHIBIT 99.1 Exhibit February 6,…
To view the full exhibit click here
About ELI LILLY AND COMPANY (NYSE:LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.